SDF-1alpha G801A Polymorphism Predicts Lymph Node Metastasis in Stage T3 Colorectal Cancer
Overview
Affiliations
Background: The SDF-1/CXCR4 axis plays an important role in cancer metastasis. SDF1alpha genetic polymorphisms, including SDF1alpha-G801A, have been associated with increased cancer risk and may be predictive of distant metastasis. The present study compared the frequency of 6 SDF1alpha single-nucleotide polymorphisms (SNPs) in patients with colorectal cancer (CRC) with and without lymph node (LN) metastasis and determined whether fibroblasts with different SDF-1alpha genotypes influenced cancer cell proliferation and migration.
Methods: The study enrolled 424 patients with primary T3 stage CRC, with and without lymph node metastasis, and a median follow-up of 48 months. The polymerase chain reaction-sequence specific primers (PCR-SSP) technique was used to identify polymorphisms. Fibroblasts were harvested from 14 patients with stage II CRC and fibroblast-mediated enhancement of cancer cell proliferation and migration was evaluated.
Results: Only the SDF1alpha-G801A polymorphism was associated with LN metastasis. The frequency of GA/AA genotypes was significantly higher in patients with LN metastasis (54.8%) than in patients without LN metastasis (40.7%). In the latter group, disease-free survival was shorter in patients with the GA/AA genotype (74%) than in patients with the GG genotype (87.6%). In patients with LN metastasis, disease-free survival was similar regardless of genotype. Expression of SDF-1alpha mRNA in GA/AA fibroblasts was three times that in GG fibroblasts. GA/AA (but not GG) fibroblasts enhanced colon cancer cell (HCT116) proliferation and migration. These effects were blocked by an SDF-1alpha neutralizing antibody.
Conclusions: The SDF1alpha-G801A polymorphism may increase expression of SDF-1alpha mRNA and be a predictive marker of lymph node metastasis in colorectal cancer.
Alghamri M, Banerjee K, Mujeeb A, Mauser A, Taher A, Thalla R ACS Nano. 2022; 16(6):8729-8750.
PMID: 35616289 PMC: 9649873. DOI: 10.1021/acsnano.1c07492.
Okuyama N, Cezar-Dos-Santos F, Trugilo K, Esposito A, Guembarovski R, Couto-Filho J J Cancer Res Clin Oncol. 2022; 148(4):793-802.
PMID: 35083551 DOI: 10.1007/s00432-021-03884-0.
Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer.
Eckert F, Schilbach K, Klumpp L, Bardoscia L, Sezgin E, Schwab M Front Immunol. 2019; 9:3018.
PMID: 30622535 PMC: 6308162. DOI: 10.3389/fimmu.2018.03018.
The CXCL12 rs1801157 polymorphism and risk of colorectal cancer: a meta-analysis.
Xu K, Dai H, Wang S, Zhang J, Liu T Onco Targets Ther. 2018; 11:2445-2452.
PMID: 29760554 PMC: 5937488. DOI: 10.2147/OTT.S151514.
Khalid S, Hanif R PeerJ. 2017; 5:e3822.
PMID: 28929029 PMC: 5602684. DOI: 10.7717/peerj.3822.